JPL CBRND Enabling Biotechnology’s mission is medical solutions during a crisis and against future threats. Our vision is to be the nation’s premier service provider enabling rapid development, manufacture, and fielding of safe and effective countermeasures for preparedness, prevention, protection, response, and recovery from CBRN threats.

OVERVIEW
JPL-CBRND is working with Ology Bioservices and Inovio Pharmaceuticals to adapt Inovio DNA technology to rapidly manufacture a DNA vaccine to prevent COVID-19 infections. The new DNA vaccine approach offers vaccine stability and ease of large scale production. This effort aims to rapidly and efficiently deliver a vaccine for use by DoD personnel.

WHY DOES DOD NEED THIS?
- There is currently no vaccine to prevent COVID-19 infection
- To ensure service members can be protected against COVID-19 infection
- To maintain strength of the Joint Force during the COVID-19 pandemic

WHAT IS THE DOD-ADM?
- Multi-product, multi-suite biomanufacturing facility
- Contractor-owned, contractor-operated (Ology Bioservices)
- cGMP compliant/BSL-3 capable
- Can support up to 4 distinct products at once
- Capacity for full production of FDA-approved products

WHY IS JPEO-CBRND SUPPORTING THIS?
- The DOD Advanced Development and Manufacturing (DOD-ADM) capability will be used to manufacture the vaccine
- Advantages of using the DOD-ADM
  - Priority access for DoD emergency requirements
  - Provides scalability and surge capacity for DoD needs

“EVEN THOUGH THIS THREAT WAS BROUGHT BY MOTHER NATURE INSTEAD OF AN ENEMY, JPEO-CBRND STILL HAS CAPABILITIES TO BRING TO THE FIGHT” - DR. JASON ROOS

Government Partners
- Office of the Assistant Secretary of Defense for Health Affairs
- Defense Health Agency

Industry Partners
- Inovio Pharmaceuticals
- Ology Bioservices

Funding: Provided by Defense Health Agency